E.U. Court Advisor Rejects Bid To Close Drug Loophole
Under the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, drug originators enjoy the right to a 20-year monopoly on their inventions. (The European Union signed on to that agreement in 1994.)
Before TRIPS, many countries provided only 15 years...
To view the full article, register now.